2024年11月5日 · Amyloid related imaging abnormalities (ARIA) represent a variety of imaging features identified in patients with Alzheimer disease being treated with novel amyloid lowering therapies such as the monoclonal antibodies bapineuzumab, solanezumab and aducanumab 1-4. In most instances, ARIA is detected incidentally on imaging.

2022年11月2日 · Amyloid-related imaging abnormalities (ARIA) is a term introduced in 2010 to encompass a spectrum of MRI findings observed in patients receiving investigational anti–amyloid beta (Aβ) immunotherapies for Alzheimer disease (AD).

Randomized clinical trials show reduced brain amyloid-β deposits using monoclonal antibodies that target amyloid-β and have identified MRI signal abnormalities called amyloid-related imaging abnormalities (ARIA) as possible spontaneous or treatment-related adverse events.

Amyloid-related imaging abnormalities (ARIA) are abnormal differences seen in magnetic resonance imaging of the brain in patients with Alzheimer's disease. ARIA is associated with anti-amyloid drugs, particularly human monoclonal antibodies such as aducanumab. [1] There are two types of ARIA: ARIA-E and ARIA-H.

Early treatment trials identified characteristic cerebral MRI imaging findings designated as ARIA‐E described as edema or sulcal effusions, and bleeding designated ARIA‐H manifested as hemosiderin deposits or small parenchymal hemorrhages.

2025年1月10日 · Here, we review the detection, underlying pathophysiological mechanisms and clinical implications of amyloid-related imaging abnormalities (ARIA), the most impactful adverse effect of anti-Aβ...

mri findings seen in amyloid-related imaging abnormalities (aria) are a consequence of the presence of amyloid in blood vessel walls (cerebral amyloid angiopathy [CAA]). 1 CAA can cause spontaneous ARIA in patients with Alzheimer’s disease (AD). 1 The risk of ARIA is

MRI signals of ARIA closely parallel those of CAA1 Monoclonal antibodies that remove amyloid plaque are associated with an increased risk for the development of two subtypes of ARIA:1,4 • ARIA-edema/effusion (ARIA-E): vasogenic edema or sulcal effusions • ARIA-hemosiderin (ARIA-H): microhemorrhages, superficial siderosis

ARIA is graded on the basis of treatment-emergent events. For ARIA-H, this count includes cumulative new microhemorrhages or regions of siderosis compared with the baseline, pretreatment examination. 7 MRI images data on ˜le ARIA-E Sulcal and/or cortical/subcortical FLAIR hyperintensity 1 location <5 cm 1 location 5–10 cm OR >1 location each ...

In human studies, the combination of PET amyloid imaging with frequent MRI monitoring in ApoE ε4 carriers receiving amyloid-lowering therapies may serve to clarify whether ARIA will occur preferentially in regions with high amyloid burden, and to demonstrate evidence of amyloid clearance proximate to ARIA.